Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Dr. Ashish Kamat Interview - BOND-003 Study Results

<< Previous

Bullboard Posts

Next >>

Comment by riverrrowon Jan 09, 2024 1:57pm

224 Views

Post# 35817820

RE:RE:RE:RE:RE:Dr. Ashish Kamat Interview - BOND-003 Study Results

Thanks for your posts everybody. I forgot how some researchers present misleading data. 75% of 75% is a little over 56%. Our CR at 270 days is 46%. I've suggested previously that once Ruvidar is FDA approved clinicians will be able to repeat Ruvidar treatment multiple times on a patient and quite possibly achieve 100% CR. GLTA.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading